1. Home
  2. Analysis
  3. Fiasp
  4. Xarelto

Fiasp and Xarelto drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among 14 people who take Fiasp and Xarelto. Common interactions include injection site discomfort among females, and insulin resistance among males.

The phase IV clinical study analyzes what interactions people who take Fiasp and Xarelto have. It is created by eHealthMe based on reports from the FDA, and is updated regularly. You may use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 700+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Sep, 24, 2023

14 people who take Fiasp and Xarelto together, and have interactions are studied.

What is Fiasp?

Fiasp has active ingredients of insulin aspart. Currently, eHealthMe is studying from 1,835 Fiasp users.

What is Xarelto?

Xarelto has active ingredients of rivaroxaban. It is used in atrial fibrillation/flutter. Currently, eHealthMe is studying from 206,346 Xarelto users.

Number of Fiasp and Xarelto reports submitted per year:

Fiasp and Xarelto drug interactions.

Common Fiasp and Xarelto drug interactions by gender *:

female:

  1. Injection site discomfort
  2. Injection site erythema
  3. Injection site inflammation
  4. Injection site rash
  5. Injection site reaction
  6. Muscle spasms
  7. Nausea
  8. Pain in extremity
  9. Renal artery stenosis
  10. Abdominal pain upper

male:

  1. Insulin resistance
  2. Blood glucose decreased
  3. Blood sodium decreased
  4. Blood urine present
  5. Brain stem haemorrhage
  6. Hospitalisation
  7. Urinary tract infection

Common Fiasp and Xarelto drug interactions by age *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

  1. Insulin resistance
  2. Blood urine present
  3. Hospitalisation
  4. Urinary tract infection

60+:

  1. Abdominal pain upper
  2. Brain stem haemorrhage
  3. Nausea
  4. Pain in extremity
  5. Renal artery stenosis
  6. Diarrhoea
  7. Injection site cellulitis
  8. Injection site discomfort
  9. Injection site erythema
  10. Injection site inflammation

Common conditions people have *:

  1. Renal Cell Carcinoma (a kidney cancer): 7 people, 50.00%
  2. Type 1 Diabetes: 2 people, 14.29%
  3. High Blood Cholesterol: 2 people, 14.29%
  4. Diabetes: 2 people, 14.29%
  5. Sleep Apnea Syndrome: 1 person, 7.14%
  6. Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 1 person, 7.14%
  7. Pericarditis (inflammation of the pericardium): 1 person, 7.14%
  8. Hyperkalemia (damage to or disease of the kidney): 1 person, 7.14%
  9. High Blood Pressure: 1 person, 7.14%
  10. Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 1 person, 7.14%

* Approximation only. Some reports may have incomplete information.

Do you take Fiasp and Xarelto?

Personalize this study to your gender and age

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related studies

Drug side effects by duration, gender and age:

Common Fiasp drug interactions:

Browse interactions between Fiasp and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Xarelto drug interactions:

Browse interactions between Xarelto and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on insulin aspart and rivaroxaban (the active ingredients of Fiasp and Xarelto, respectively), and Fiasp and Xarelto (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study. Patients in the study may take other drugs besides Fiasp and Xarelto.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 700+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2023 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.